MSH2 and colorectal cancer: In summary, patients in these families all revealed loss of MSH2 staining by immunohistochemistry (IHC) and hypermethylation of the MSH2 promoter within the colorectal cancers, as well as methylation of the MSH2 promoter across various normal tissues, although to a variable extent.